What percentage of patients with invasive ductal carcinoma stage IIB, Ki-67 approximately 1%, estrogen receptor positive and progesterone receptor positive, HER2-negative achieve remission after treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Remission Rates for Stage IIB ER+/PR+/HER2- Invasive Ductal Carcinoma with Ki-67 1%

With a Ki-67 of only 1%, this tumor represents an extremely favorable biology profile, and you should expect excellent outcomes with endocrine therapy alone—likely achieving disease-free survival rates exceeding 90% at 5 years, though specific "remission" percentages for this exact profile are not reported in the literature because these patients typically undergo surgery first, not neoadjuvant therapy where pathologic complete response (pCR) is measured.

Understanding the Clinical Context

Your patient's tumor has exceptionally favorable characteristics:

  • Ki-67 of 1% is extraordinarily low (well below the typical 5% threshold for "low proliferation")
  • Strong ER/PR positivity indicates high hormone responsiveness
  • Stage IIB means either T2N1 or T3N0 disease
  • HER2-negative confirms this is a luminal-type cancer

Why "Remission Rates" Are Not Directly Reported

The evidence base doesn't provide specific "remission percentages" for this profile because:

  1. Surgery is first-line treatment: For HR+/HER2- breast cancer with favorable biology, surgery is the initial treatment modality 1. Neoadjuvant therapy is reserved for larger tumors requiring downstaging.

  2. pCR is uncommon in this subtype: Even when HR+/HER2- cancers receive neoadjuvant chemotherapy, pathologic complete response rates are very low (<10%) 2. However, this doesn't reflect poor outcomes—it reflects that these tumors respond better to endocrine therapy than chemotherapy.

  3. Low Ki-67 predicts poor chemotherapy response: Research shows that patients with Ki-67 ≤24% have particularly low pCR rates with neoadjuvant chemotherapy, especially with high ER expression 2. Your patient's Ki-67 of 1% falls far below this threshold.

Expected Treatment Approach and Outcomes

Recommended Treatment Algorithm:

For Stage IIB with Ki-67 1% and strong ER/PR positivity:

  • Primary surgery (not neoadjuvant therapy) 1
  • Adjuvant endocrine therapy is the cornerstone:
    • If postmenopausal: Aromatase inhibitor for 5-10 years 1
    • If premenopausal: Consider ovarian function suppression + AI or tamoxifen, especially if N1 disease 1, 3
  • Chemotherapy consideration: With this favorable biology (Ki-67 1%, strong ER/PR), chemotherapy would likely be omitted in most scenarios 1, 3
    • The 2023 St. Gallen consensus indicates that for favorable biology tumors (low Ki-67, strongly ER-positive), chemotherapy may not be warranted even in Stage II disease 3
    • Genomic testing (Oncotype DX, MammaPrint) would likely show low-risk scores, further supporting endocrine therapy alone

Expected Outcomes:

While exact "remission" rates aren't specified for this profile, the prognosis is excellent:

  • Adjuvant chemotherapy reduces relative recurrence risk by 25-30% across all subtypes 1, but the absolute benefit in low-risk biology is minimal
  • Endocrine therapy alone in favorable biology tumors (like yours) provides excellent disease control
  • 5-year disease-free survival for Stage II, ER+/HER2-, low-proliferation tumors typically exceeds 85-90% with appropriate endocrine therapy
  • Extended endocrine therapy (7-10 years) further reduces recurrence risk, particularly in Stage II disease 1

Critical Clinical Pitfalls

Do not equate low pCR rates with poor prognosis in HR+ disease. The research shows that ER-negative tumors and high Ki-67 tumors achieve better pCR rates with chemotherapy 4, 5, but this reflects chemosensitivity, not overall prognosis. Your patient's tumor biology predicts excellent long-term outcomes with endocrine therapy, despite low expected pCR if chemotherapy were given.

The Ki-67 of 1% is a powerful favorable prognostic marker. Studies demonstrate that Ki-67 >13% independently predicts both treatment response and prognosis 5, and your patient falls far below this threshold, indicating very low proliferative activity and excellent prognosis.

Additional Considerations for Stage IIB

If your patient has 1-3 positive lymph nodes (N1):

  • Consider adjuvant bisphosphonates if postmenopausal 1
  • Extended endocrine therapy becomes more important 1, 3
  • Abemaciclib (CDK4/6 inhibitor) for 2 years could be considered if high-risk features beyond just stage (though with Ki-67 1%, this patient doesn't meet typical high-risk criteria) 1

In practical terms: expect this patient to do extremely well with surgery followed by 5-10 years of endocrine therapy, with disease-free survival likely exceeding 90% at 5 years.

References

Related Questions

What is the recommended treatment for a patient with invasive ductal carcinoma, Ki‑67 1 %, nuclear grade 1, HER2‑negative, hormone‑receptor‑positive disease and four positive axillary lymph nodes?
For a 58-year-old woman with a 3.2 cm, grade 2, estrogen‑receptor‑positive, progesterone‑receptor‑positive, HER2‑negative invasive ductal carcinoma, two positive axillary lymph nodes, high clinical risk, and a low Prosigna (PAM50 Risk of Recurrence) score, what is the most appropriate adjuvant treatment step according to the OPTIMA trial presented at ASCO 2026?
In a patient with grade 1 invasive ductal carcinoma, Ki‑67 1%, HER2‑negative and hormone‑receptor‑positive, does chemotherapy provide benefit?
What is the appropriate management for a 70‑year‑old woman with a 1.8 cm right‑sided ductal carcinoma in situ with microinvasion that is estrogen‑receptor positive, progesterone‑receptor negative, and HER2 positive?
For a female patient with invasive ductal carcinoma grade 2 (estrogen‑receptor low positive, progesterone‑receptor negative, HER2‑negative, Ki‑67 40%) who completed neoadjuvant doxorubicin‑cyclophosphamide plus toripalimab, paclitaxel‑carboplatin plus toripalimab, surgery (ypT0N0), adjuvant radiotherapy and one year of toripalimab, is now on anastrozole and has mild back pain with imaging showing multiple spinal bone metastases, what is the next step in management?
Can aripiprazole (Abilify) be used to treat anxiety, and what is the recommended dosing and monitoring?
For an HSV-positive mother whose newborn was treated at birth, how long should she continue pumping and discarding breast milk?
What is the appropriate dosing of vancomycin and piperacillin‑tazobactam (Zosyn) for a 44-year-old man with suspected osteomyelitis and foot cellulitis?
What is the recommended hospital treatment protocol for an acute moderate-to-severe COPD exacerbation?
What is an appropriate tapering schedule to discontinue duloxetine 90 mg daily?
What is the recommended antiviral and supportive treatment for influenza in adults and children, including dosing and considerations for high‑risk patients?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.